Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy
Youngman MJ, Rogers ZN, Kim DH
GHK-Cu demonstrates greater stability than BPC-157, remaining potent at room temperature for extended periods
You will discard unused peptide when the 28-day post-reconstitution deadline expires
The three major routes of administration used for skin lightening are topical (creams, face washes), oral (capsules and sublingual/buccal tablets) and intravenous injections
These studies show which factors (cholesterol, visceral fat, inflammation, and sex) modify the risk of high Lp(a)
